“We had the opportunity to really get in under the hood. [Moderna] is a company that we’ve talked with and known for quite a long time. So we had the opportunity to look at them very carefully and to look at the data that they’ve produced preclinically, and frankly it’s enormously impressive. The translation to humans, of course, will have its challenges but it’s something that we felt we were in a relatively unique position to pursue and so did they. I have to tell you the nature of those interactions has been extremely positive.”
Dr. Roger M. Perlmutter, president of Merck Research Laboratories, as quoted in Forbes.
Moderna signs a license and collaboration agreement with Merck for the discovery and development of vaccines and passive immunity treatments against viral diseases using modified mRNA.
Messenger RNA is an entirely new class of therapeutics, led by the Moderna team’s leading know-how and vast intellectual property.
Our scale and speed sets us apart – we can generate thousands of mRNA constructs a year for research and non-clinical testing, with a cycle time of weeks.
We are creating a unique ecosystem of in-house teams and partners to develop the broadest array of drugs imaginable.
To deliver on the promise of transformative messenger RNA (mRNA) science to bring new medicines to patients.
Spotlight on Moderna
Recent Press Releases
January 8, 2015
Moderna Launches New Venture Valera LLC for Infectious Diseases
Moderna venture to advance mRNA vaccines and mRNA-based passive immunity therapies
January 7, 2015
Onkaido Announces Appointment of Michael J. Morin, Ph.D., as Chief Scientific Officer
Former Pfizer research executive to lead scientific efforts in oncology drug development leveraging Moderna’s messenger RNA Therapeutics™ platform